Affinity Asset Advisors LLC Acquires 396,850 Shares of Savara Inc (NASDAQ:SVRA)

Affinity Asset Advisors LLC grew its holdings in Savara Inc (NASDAQ:SVRA) by 34.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,546,850 shares of the company’s stock after buying an additional 396,850 shares during the period. Affinity Asset Advisors LLC owned approximately 1.12% of Savara worth $6,234,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. CANADA LIFE ASSURANCE Co purchased a new position in Savara in the first quarter worth about $35,000. Choreo LLC purchased a new stake in Savara during the second quarter valued at approximately $59,000. DRW Securities LLC bought a new stake in shares of Savara in the 2nd quarter valued at approximately $62,000. Principal Financial Group Inc. boosted its holdings in shares of Savara by 64.4% in the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after purchasing an additional 6,973 shares during the period. Finally, Profund Advisors LLC bought a new position in shares of Savara during the 2nd quarter valued at approximately $105,000. 87.93% of the stock is currently owned by institutional investors.

Savara Stock Performance

SVRA stock opened at $4.42 on Wednesday. Savara Inc has a 12 month low of $3.12 and a 12 month high of $5.70. The firm’s 50-day moving average is $4.37 and its 200 day moving average is $4.47. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). On average, analysts anticipate that Savara Inc will post -0.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SVRA has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Savara in a research report on Wednesday, August 14th. Guggenheim raised their target price on shares of Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. JMP Securities reiterated a “market outperform” rating and set a $9.00 price target on shares of Savara in a report on Monday, September 9th. Finally, Oppenheimer increased their price objective on shares of Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 26th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $11.17.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.